Global Ophthalmology Conference 2025

On April 17, 2025, the first Global Ophthalmology Conference 2025, hosted by EyeFuture | Siyu MedTech and co-organized by Zhongguancun Lianxin Biomedical Industry Alliance, Beijing Zhongguancun Science City Innovation Development Co., Ltd., Beijing Zhongguancun Venture Street Technology Service Co., Ltd., TusStar, and Zhongguancun Science City CGT Industry Incubation Center, was grandly held at the Zhongguancun National Innovation Demonstration Zone Exhibition & Trading Center in Beijing.

The conference brought together top experts and core corporate representatives from medical devices, clinical medicine, artificial intelligence, life sciences, investment and policy sectors. Over 600 attendees were present on-site, marking an unprecedented grand event. Adopting a cross-border integration perspective of "Policy + Technology + Translation + Capital", the conference focused on the full-scale development of the ophthalmic industrial chain, presenting a highly professional and forward-looking industry summit.

The opening ceremony was hosted by Zhao Qing, founder of Siyu MedTech healthcare media and Secretary-General of Zhongguancun Lianxin Biomedical Industry Alliance.

Lin Hang, Deputy District Chief of Haidian District, stated in her opening address that eye health constitutes an important part of the national health strategy.

Haidian District will continue to promote the initial local translation and application of scientific and technological achievements in ophthalmic medical devices, artificial intelligence, biomaterials and other fields through an integrated four-pronged approach of "Data + Scenarios + Space + Mechanism". She expressed that Haidian is willing to serve as the primary platform for the innovative medical ecosystem, providing higher-quality growth ground for clinical experts, researchers and entrepreneurs.

Liu Hui, Director of Beijing Medical and Health Technology Development Center, said that Beijing is comprehensively advancing the implementation of the dual-engine strategy for medical health and artificial intelligence, establishing a full-lifecycle mechanism supporting innovative drugs and devices in terms of space carriers, financial support, test verification and market access. She specifically mentioned that ophthalmic innovation featuring "small incisions, large application scenarios" has become one of the key development directions strongly encouraged by Beijing.

Professor Ren Qiushi, Department of Biomedical Engineering, School of Future Technology, Peking University, National Distinguished Young Scholar, Yangtze River Scholar, Fellow of the American Institute for Medical and Biological Engineering and Fellow of the International Society for Optics and Photonics, pointed out that ophthalmology is one of the rare disciplines featuring high-level intersection of imaging, materials science, stem cell research and neuroscience. Only through deep coupling between engineering and clinical practice can the translational realization of "from technology to therapeutic efficacy" be truly achieved.

At the conference, the 2025 Global Ophthalmic Innovation Annual White Paper, jointly compiled by EyeFuture and Siyu MedTech with data support from the High-End Medical Device Institute Data Center, was officially released. The 80,000-word main text covers multiple dimensions including the global and Chinese ophthalmic market landscape, technological development, investment and financing trends, and innovative enterprise cases, offering systematic references for the industry. (A detailed article will be published later.)

The presentation of the Global Ophthalmic Innovation Series Awards was another exciting highlight of the conference. The awards recognized enterprises and individuals with fruitful achievements in ophthalmic technological breakthroughs, clinical application and model innovation, as well as overseas market expansion over the past year. The awards aim to encourage original innovation "rooted in China and influencing the world", and drive innovation to move closer to clinical practice.

(See the link for the full article: Freshly Released! 29 Awards! 2025 Global Ophthalmic Innovation Series Awards)

The membership awarding ceremony for Zhongguancun Lianxin Biomedical Industry Alliance was held concurrently. The alliance welcomed new corporate members from multiple sub-sectors including medical devices, digital health, drug R&D and medicine-engineering intersection, demonstrating that "cross-border integration + collaboration" has become the mainstream trend of modern pharmaceutical innovation.

During the policy interpretation session of the opening ceremony, three representatives from key government departments of Beijing delivered policy signals and practical suggestions most concerned by the drug and device sector. (Full content will be released in follow-up articles.)

Wang Shijun from the Medical Service Management Division of Beijing Medical Security Bureau gave a detailed interpretation of Several Measures of Beijing Municipality for Supporting High-Quality Development of Innovative Medicines (2025).

Wang Wei, Deputy Director of the Policy and Regulations Division of Beijing Drug Administration, introduced new supporting measures rolled out by Beijing Drug Administration in 2025.

Cheng Wanhui, Director of the Third Industrial Promotion Division of Zhongguancun Science City Administrative Committee, shared Biomedical Industry Environment and Policies in Haidian District.

Gathering of Experts, Collision of Perspectives

The morning agenda centered on "Technological Innovation and Medicine-Engineering Integration", focusing on cutting-edge ophthalmic fields such as AI, imaging, pharmaceuticals and surgical robots.

The morning keynote forum was hosted by Ye Jing, senior analyst of the healthcare industry at Northeast Securities.

Professor Ren Qiushi from the Department of Biomedical Engineering, School of Future Technology, Peking University, delivered a speech titled Multimodal Ocular-Cardiac-Brain Functional Imaging and Its Application in Chronic Disease Management. He pointed out that multimodal technology integrating electroencephalography, electrocardiography and ocular imaging enables more accurate identification of early chronic disease risks, realizing the leap from single-organ diagnosis to systematic management.

Chang Xiangang, CEO of Airdoc, shared Exploration of Wanyu Large Model Application in Healthcare Scenarios. He demonstrated how AI large models can exert capabilities in multiple scenarios such as fundus images, physical examinations and chronic disease prediction, and emphasized that data-driven medical AI must be built upon "repeated verification and iteration" in real-world scenarios.

Jing Boyang, Senior Researcher at Shenzhen Ruitong Biomedicine Co., Ltd., presented *Challenges and Opportunities of Long-Acting Ophthalmic Drugs*. He noted that in ophthalmic drug development, long-acting formulations face challenges in biodegradability and safety, yet also provide new pathways for chronic disease treatment and adherence management.

Lin Chuang, Chief Technology Officer of Beijing Xianwei Medical Technology Co., Ltd., delivered a report titled *Opportunities and Challenges of Ophthalmic Surgical Robots*. He stated that surgical robots represent key technologies to improve surgical precision and efficiency in the future. For ophthalmology’s special scenario featuring narrow operating space and high precision requirements, miniaturization of instruments and visualization of operations are important breakthrough directions for the next stage.

Wang Xiaofei, Professor at Beihang University and Doctoral Supervisor at Wenzhou Medical University, shared *Exploration and Practice of Ophthalmic Medicine-Engineering Integrated Research*. As an engineer, he has long been deeply involved in research on frontline clinical demands. By introducing several commercialized product cases, he stressed that the approach of "identifying problems from surgical procedures and developing solutions based on principles" serves as the core translational logic for realizing medicine-engineering integration.

The subsequent roundtable forum, hosted by Ye Jing from Northeast Securities, discussed Opportunities amid Turmoil: Ophthalmic Investment & Financing, Policy Changes and Innovation Frontiers. Wang Lejin, Chief Ophthalmologist at Peking University People’s Hospital, shared the shifting role of clinicians in innovation translation from a clinical perspective. Miao Siyu, Partner at Volcano Stone Investment, focused on capital’s concerns over technological verification and industrialization paths. Professor Wang Xiaofei from Beihang University and Xia Chaoran, CEO of Huashi Novi, also shared insights from academia and enterprises on how innovative companies can steadily advance technological breakthroughs amid uncertain environments.

Scenario Extension: From Clinical Demands to Technological Implementation

The afternoon forum was hosted by Zhao Chan from Peking Union Medical College Hospital and Peng Rongmei from Peking University Third Hospital.

Wang Zewei, Head of Strategic Investment Department at Guoke Hengtai, presented *Analysis of Medical Device Commercialization Paths under Volume-Based Procurement*. She pointed out that against the backdrop of normalized volume-based procurement, enterprises need to consider product pricing, channel management and surgical substitution strategies at an earlier stage to strike a balance between innovation and accessibility. She also emphasized that establishing clinical "irreplaceability" of products in the early phase is critical to weathering the volume-based procurement cycle.

Hong Jing, Director of the Ophthalmology Department of Peking University Third Hospital, delivered a speech titled Innovative Technologies Boost Ophthalmic Development. She introduced multiple achievements of her team with translational potential. EyeFuture will elaborate on them one by one in follow-up articles.

Xu Yi, President of Wuyixi, shared *From Treatment to Preventive Care: Scenario Experience Innovation of Mobile Atomized Eye Care*. He described the trend of eye health management shifting from "passive treatment" to "active eye care and maintenance". He showcased mobile application scenarios based on atomization devices and put forward the concept of eye care "similar to oral care", which is expected to become a new type of healthcare method for household scenarios.

Dr. Lin introduced the research Development and Exploration of Wide-Field Retinal Refraction Topographer on behalf of Lan Weizhong, Vice President of Aier Eye Hospital Research Institute, Central South University. Integrating retinal imaging and refraction measurement technologies, this device features dual functions of full-field imaging and refraction analysis, and is expected to achieve breakthroughs in multiple areas including myopia prevention and control and fundus disease screening.

Zhang Shaomin, Chief Scientist of Shibiao Medical Technology / Kebiao Medical Group, presented The Importance of In Vivo Studies in Concept Verification and Non-Clinical Trials for New Ophthalmic Devices. He noted that many innovative products are terminated in the non-clinical phase due to unclear verification pathways, and stressed an experimental strategy of "early planning + long-term follow-up" to improve the success rate of device transition from design to clinical application.

Li Yingjun, General Manager of Beijing Tonghe Litai Biotechnology Co., Ltd., delivered a speech on Innovative Research and Preclinical Animal Experiments of Ophthalmic Medical Devices. He analyzed common pitfalls for enterprises in the process "from prototype to registration application" in terms of laboratory animal models and research process compliance, and proposed a potential pathway to set up a "pre-clinical accelerator".

Zhao Chan, Chief Ophthalmologist at Peking Union Medical College Hospital, shared Core Technological Innovation and Surgical Prospect of Intraocular Minimally Invasive Intervention. He introduced the scientific and technological achievement translation work he participated in and related outcomes. EyeFuture will publish a detailed article later.

Zhao Zhongheng, Medical Director of Bangxun Medical Technology, explained Application of Overseas Clinical Trial Data in the Registration Submission of Ophthalmic Products. Combining registration pathway cases, he pointed out that China’s drug regulatory authorities have gradually raised acceptance standards for overseas data. Meanwhile, he proposed that enterprises should proactively adopt a "data mapping" strategy adapted to Chinese regulations to avoid registration barriers caused by differences in trial design.

Peng Rongmei, Professor of Ophthalmology at Peking University Third Hospital, delivered a talk on Ocular Cell Therapy: Restoring Sight for Blind Patients. Stay tuned for EyeFuture’s follow-up interview with Professor Peng.

Zhang Jinlu, student of Yang Liping, Researcher of Ophthalmology at Peking University Third Hospital, presented Research and Development of Gene Therapy Drugs for Crystalline Retinal Degeneration. She elaborated on the pathogenesis and target selection of this rare eye disease, analyzed key nodes including viral vector design and animal model verification, and emphasized that clinical indication design needs to balance "controllability" and "registrability".

Liu Bing, Associate Researcher at the Institute of Automation, Chinese Academy of Sciences, delivered a report on Brain-Computer Interface and Visual Reconstruction for Totally Blind Patients. He presented experimental results of partial image perception reconstruction for totally blind populations via electrode array stimulation of the visual cortex of the brain, and held that brain-computer interface will become one of the most disruptive directions in the field of visual reconstruction in the next decade.

Wang Yuchen, Attending Ophthalmologist at Peking University Third Hospital, shared *Multi-Modal Dynamic Visual Acuity Examination, Training and Improvement Device and Platform*. See follow-up EyeFuture articles for full details.

Building Bridges, Opening a New Chapter for the Future of Ophthalmology

As China’s first cross-disciplinary conference focusing on ophthalmic technological innovation and medicine-engineering integration, the Global Ophthalmology Conference serves not only as an exchange summit for industry and academia, but also as a concentrated showcase of medicine-engineering translation practices.

This platform jointly built by Siyu MedTech and EyeFuture strives to become a bridge connecting engineers, clinicians, entrepreneurs and investors in the ophthalmology sector.

Going forward, EyeFuture will continue to update ophthalmic innovative technologies, corporate developments and global trends, helping more technologies move out of laboratories and into clinical practice and the market.